Clinical Trial Update: Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by TACE-HAIC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating low-dose bevacizumab plus adebrelimab with transarterial chemoembolization followed by TACE-HAIC for hepatocellular carcinoma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Adebrelimab (adebrelimab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Third Affiliated Hospital, Sun Yat-Sen University | Conditions: Adebrelimab (SHR-1316), Bevacizumab | Phase 2 | Status: NOT_YET_RECRUITING